Micromet is a company dedicated to research and development. Micromet designs and develops innovative antibody-based drugs for the treatment of autoimmune and inflammatory diseases and cancer. Micromet’s therapeutic strategy is the eradication of cells playing a crucial role in the pathogenesis of diseases by recruiting and activating immune effector cells. The company has established the BiTE™ technology (bispecific T-cell engagers), a drug format that leverages the cytotoxic potential of T-cells.